Dutch fuel on the fire.

There are few routine lab controversies more heated than the role of prostate-specific antigen (PSA) screening for otherwise healthy middle-age men. The ERSPC Rotterdam trial now has 20-year results demonstrating that routine PSA screening every 4 years for men ages 55 to 75 slashes incidence of prostate cancer metastases and mortality in half. | Osses, Eur Urol 2018